Abstract:The Hedgehog (Hh) signaling pathway plays a critical role in controlling patterning, growth and cell migration during embryonic development. Aberrant activation of Hh signaling has been linked to tumorigenesis in various cancers, such as basal cell carcinoma (BCC) and medulloblastoma. As a key member of the Hh pathway, the Smoothened (Smo) receptor, a member of the G protein-coupled receptor (GPCR) family, has emerged as an attractive therapeutic target for the treatment and prevention of human cancers. The recent determination of several crystal structures of Smo in complex with different antagonists offers the possibility to perform structure-based virtual screening for discovering potent Smo antagonists with distinct chemical scaffolds. In this study, based on the two Smo crystal complexes with the best capacity to distinguish the known Smo antagonists from decoys, the molecular docking-based virtual screening was conducted to identify promising Smo antagonists from ChemDiv library. A total of 21 structurally novel and diverse compounds were selected for experimental testing, and six of them exhibited significant inhibitory activity against the Hh pathway activation (IC50 < 10 μM) in a GRE (Gli-responsive element) reporter gene assay. Specifically, the most potent compound (compound 20: 47 nM) showed comparable Hh signaling inhibition to vismodegib (46 nM). Compound 20 was further confirmed to be a potent Smo antagonist in a fluorescence based competitive binding assay. Optimization using substructure searching method led to the discovery of 12 analogues of compound 20 with decent Hh pathway inhibition activity, including four compounds with IC50 lower than 1 μM. The important residues uncovered by binding free energy calculation (MM/GBSA) and binding free energy decomposition were highlighted and discussed. These findings suggest that the novel scaffold afforded by compound 20 can be used as a good starting point for further modification/optimization and the clarified interaction patterns may also guide us to find more potent Smo antagonists.

Discovery and Characterization of a Small Molecule Inhibitor of the PDZ Domain of Dishevelled

Synthesis of Potent Dishevelled PDZ Domain Inhibitors Guided by Virtual Screening and NMR Studies

Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with <i>in vivo</i> antitumor activity

Discovery and Characterization of a Potent Wnt and Hedgehog Signaling Pathways Dual Inhibitor.

Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors Using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (Sam)-Dependent Methyltransferase Family.

Inhibiting The Wnt Signaling Pathway With Small Molecules

Design, Synthesis, and Evaluation of Potent Wnt Signaling Inhibitors Featuring a Fused 3-Ring System.

Discovery of DDO-2213 As a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia

Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays.

Ultra-large scale virtual screening identifies a small molecule inhibitor of the Wnt transporter Wntless

Discovery of small-molecule inhibitors of RUVBL1/2 ATPase

Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety.

Structure-Based Ligand Discovery Targeting the Transmembrane Domain of Frizzled Receptor FZD7

Discovery of Small Molecule Inhibitors Targeting the Sonic Hedgehog

Discovery of Potent and Novel Smoothened Antagonists Via Structure-Based Virtual Screening and Biological Assays.

Structure-Based Design and Synthesis of Small Molecular Inhibitors Disturbing the Interaction of Mll1-Wdr5

Modulating the wnt signaling pathway with small molecules

Discovery of Novel Inhibitor for WNT/-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening

Small-molecule synergist of the Wnt/beta-catenin signaling pathway.

Characterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling

Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen